Are you Dr. Tetzlaff?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 49 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Michael Tetzlaff, MD is a board certified pathologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alaska, and Illinois. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of Pennsylvania Health SystemFellowship, Dermatopathology, 2009 - 2010- University of Pennsylvania Health SystemResidency, Pathology-Anatomic and Clinical, 2005 - 2009
Baylor College of MedicineClass of 2005
Certifications & Licensure
AK State Medical License 2022 - 2026
CA State Medical License 2020 - 2026
IL State Medical License 2021 - 2026
TX State Medical License 2010 - 2025
PA State Medical License 2005 - 2010
American Board of Pathology Pathology - Anatomic- American Board of Pathology Dermatopathology
Publications & Presentations
PubMed
- Cytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status.Tatsiana Pukhalskaya, Mitchell Finkelstein, Dacia A Miyake-Caballero, Michael T Tetzlaff, Jeffrey P North
Journal of Cutaneous Pathology. 2025-03-01 - Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing.Janis M Taube, Joel C Sunshine, Michael Angelo, Guray Akturk, Margaret Eminizer
Journal for Immunotherapy of Cancer. 2025-01-08 - Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.Reinhard Dummer, Caroline Robert, Richard A Scolyer, Janis M Taube, Michael T Tetzlaff
Nature Medicine. 2025-01-01
Press Mentions
Lichenoid Dermatitis with Mycosis Fungoides Features Linked to Checkpoint Inhibitor TherapyJuly 28th, 2019
Dual Neoadjuvant Checkpoint Blockade Feasible in MelanomaOctober 11th, 2018
Neoadjuvant Combination Checkpoint Blockade Trial Yields High Response Rates for Patients with High-Risk Stage Three MelanomaOctober 8th, 2018- Join now to see all
